In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Reduction of NT-proBNP in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction in short-term treatment with empagliflozin on top of existing therapy

Session Poster Session 3

Speaker Branimir Kanazirev

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure: Pharmacotherapy
  • Session type : Poster Session

Authors : B Kanazirev (Varna,BG), A Dinkov (Varna,BG), K Hristozov (Varna,BG), E Marinova (Varna,BG), V Zlateva (Varna,BG), M Boyadjieva (Varna,BG), Y Bocheva (Varna,BG)

Authors:
B Kanazirev1 , A Dinkov1 , K Hristozov1 , E Marinova1 , V Zlateva1 , M Boyadjieva1 , Y Bocheva1 , 1Medical University of Varna - Varna - Bulgaria ,

Citation:

Objective: To investigate effect of SGLT-2 inhibitor on NT-pro-BNP levels, physical capacity and selected echocardiographic parameters in patients with type 2 diabetes (T2 DM) and heart failure with preserved  ejection fraction (HFpEF)

Materials and Methods: Empagliflozin 10 mg/daily was administered to 24 T2DM and HFpEF patients (64.3±7.7) on top of pre-existing standard therapy. NT-proBNP, glomerular filtration rate (GFR), 6-minute test (6MWT), left atrial area (LAA), left ventricular ejection fraction (LVEF) and systolic blood pressure( SBP) were investigated on day 30.

Results: NT-proBNP decreased after 30 days of treatment with Empagliflozin added to standard patient therapy. 6MT, LVEF and LAA and SBP show a tendency for improvement and the GFR decreased insignificantly.

NT-pro BNP

GFR

6?W?

LAA

LVEF

SBP

Before

1104±1078*

76±13**

266±88**

23.9±5.9**

57.2±5.5**

135±15**

Day 30

565±439

73±12

311±123

22.6±4.7

60.8±5.9

132±13

*p=0.0039 **p>0.05

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are